Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

IGF1R as druggable target mediating PI3K-δ inhibitor resistance in a murine model of chronic lymphocytic leukemia

Blood (2019) 134 (6): 534–547.

https://doi.org/10.1182/blood.2018881029

Published: 2019

Includes: Supplemental data

Journal Articles

Acute Lymphoblastic Leukemia Cells Bypass the Blood Brain Barrier to Enter the CNS Via a Neuronal Developmental Pathway

Hisayuki Yao, MD PhD, Matthew Warner, PhD, Trevor Price, PhD, Lindsey Olivere, Gaia Cantelli, PhD, Sarah Ridge, PhD, Brandon Ngo, Surya Ravichandran, Stacey Tannheimer, PhD, Anjen Chenn, MD PhD, Dorothy A. Sipkins, MD

Blood (2017) 130 (Supplement 1): 144.

https://doi.org/10.1182/blood.V130.Suppl_1.144.144

Published: 2017

Journal Articles

The BET Inhibitor GS-626510 Converges with Idelalisib through the Inhibition of Tumor-Macrophage Crosstalk and Cytokine Production in Diffuse Large B-Cell Lymphoma

Juan G Valero, PhD, Aranzazu Chamorro-Jorganes, PhD, Katie Walker, PhD, Martina Guerrero-Hernandez, MSc, Vanina Rodriguez, Clara Recasens-Zorzo, MSc, Anna Esteve-Arenys, MSc, Eriong Lee-Verges, MSc, Alba Matas-Cespedes, PhD, Neus Serrat, PhD, Dolors Colomer, PhD, Armando Lopez-Guillermo, Stacey Tannheimer, PhD, Patricia Pérez-Galán, PhD, Gael Roue, PhD

Blood (2017) 130 (Supplement 1): 4108.

https://doi.org/10.1182/blood.V130.Suppl_1.4108.4108

Published: 2017

Journal Articles

Enhanced Efficacy of the SYK Inhibitor Entospletinib and Chemotherapy in Infant Acute Lymphoblastic Leukemia

Joseph Patrick Loftus, BS, Anella Yahiaoui, BS, Feng Shen, MDPhD, David Lopez, Igor Mikaelian, DVM, Patrick A Brown, MD, Stacey Tannheimer, PhD, Ann Forslund, PhD, Sarah K Tasian, MD

Blood (2017) 130 (Supplement 1): 2611.

https://doi.org/10.1182/blood.V130.Suppl_1.2611.2611

Published: 2017

Journal Articles

Idelalisib Interferes with the Crosstalk of Follicular Lymphoma and Its Immune Microenvironment and Potentiates the Activity of ABT-199

Martina Guerrero-Hernandez, MSc, Alba Matas-Cespedes, PhD, Neus Serrat, PhD, Anella Yahiaoui, BS, Juan G Valero, PhD, Laura Magnano, MD, Alfredo Rivas-Delgado, MD, Dolors Colomer, PhD, Elias Campo, MD PhD, Armando Lopez-Guillermo, Gael Roue, PhD, Stacey Tannheimer, PhD, Patricia Pérez-Galán, PhD

Blood (2017) 130 (Supplement 1): 2813.

https://doi.org/10.1182/blood.V130.Suppl_1.2813.2813

Published: 2017

Journal Articles

BI 836826, a Novel Fc-Engineered Antibody in Combination with Phosphoinositide-3-Kinase Inhibitor for Treatment of High Risk Chronic Lymphocytic Leukemia and Lymphoma

Deborah M Stephens, DO, Kyle A. Beckwith, PhD, Priscilla Do, BS, Carolyn Cheney, BS, Xiaokui Mo, PhD MAS, Karilyn Larkin, MD, Jeffrey Jones, MD MPH, Farrukh T. Awan, Laura Grosmaire, PhD, Randy Jones, PhD, Julie DiPaolo, PhD, Stacey Tannheimer, Karl-Heinz Heider, PhD, John C. Byrd, MD, Natarajan Muthusamy, DVM, PhD

Blood (2016) 128 (22): 2767.

https://doi.org/10.1182/blood.V128.22.2767.2767

Published: 2016

Journal Articles

PI3Kδ Inhibition Suppresses Central Nervous System Involvement of Acute Lymphoblastic Leukemia

Hisayuki Yao, MD PhD, Trevor Price, PhD, Lindsey Olivere, Matthew Warner, PhD, Stacey Tannheimer, Dorothy A. Sipkins, MD PhD

Blood (2016) 128 (22): 282.

https://doi.org/10.1182/blood.V128.22.282.282

Published: 2016

Journal Articles

Evaluation of Idelalisib with B-Cell Receptor or Orthogonal Pathway Inhibitors in Diffuse Large B-Cell Lymphoma Cell Lines in Vitro and In Vivo

Sarah Meadows, Anella Yahiaoui, Rick Sorensen, Zhi-Hua Cui, PhD, Robert Brockett, Kathleen S Keegan, PhD, Stacey Tannheimer

Blood (2016) 128 (22): 1845.

https://doi.org/10.1182/blood.V128.22.1845.1845

Published: 2016

Journal Articles

In Vivo modeling of Resistance to PI3Kδ Inhibitor Treatment Using EµTCL1-Tg Tumor Transfer Model

Annika Scheffold, Billy Michael Chelliah Jebaraj, Eugen Tausch, Anella Yahiaoui, Anna Dolnik, PhD, Tamara Jacqueline Blaette, M.sc., Lars Bullinger, MD, Christof Schneider, MD, Daniel Mertens, PhD, Veerendra Munugalavadla, Shih-Shih Chen, PhD, Nicholas Chiorazzi, MD, Stacey Tannheimer, Hartmut Döhner, MD, Stephan Stilgenbauer

Blood (2016) 128 (22): 190.

https://doi.org/10.1182/blood.V128.22.190.190

Published: 2016

Journal Articles

Combination of the BET Inhibitor GS-5829 and a BCL2 Inhibitor Resulted in Broader Activity in DLBCL and MCL Cell Lines

Jamie Bates, Saritha Kusam, Stacey Tannheimer, Astrid Clarke, Thomas Kenney, David Breckenridge, Daniel Tumas

Blood (2016) 128 (22): 5104.

https://doi.org/10.1182/blood.V128.22.5104.5104

Published: 2016

Journal Articles

The Combination of a BET Inhibitor (GS-5829) and a BTK Inhibitor (GS-4059) Potentiates DLBCL Cell Line Cell Death and Reduces Expression of MYC, IL-10, and IL-6 in Vitro

Jamie Bates, Saritha Kusam, Stacey Tannheimer, Julie Chan, Yvonne Li, David Breckenridge, Daniel Tumas

Blood (2016) 128 (22): 5116.

https://doi.org/10.1182/blood.V128.22.5116.5116

Published: 2016

Journal Articles

PI3Kδ Inhibition Elicits Anti-Leukemic Effects through Bim-Dependent Apoptosis

Matthew J Carter, PhD, Kerry L Cox, Stuart J Blakemore, Anna H Turaj, MSc, Robert J Oldham, Lekh N. Dahal, PhD, Stacey Tannheimer, Francesco Forconi, MD DM, PhD FRCPath, Graham Packham, PhD, Mark S Cragg, PhD

Blood (2016) 128 (22): 3241.

https://doi.org/10.1182/blood.V128.22.3241.3241

Published: 2016

Journal Articles

Investigation of the Mechanism of Idelalisib Resistance in the Follicular Lymphoma WSU-Fsccl Cell Line

Rick Sorensen, BS, Sarah Meadows, Anella Yahiaoui, BS, Li Li, PhD, Peng Yue, PhD, Adam Kashishian, BS, Christophe Queva, PhD, Stacey Tannheimer, PhD

Blood (2015) 126 (23): 2482.

https://doi.org/10.1182/blood.V126.23.2482.2482

Published: 2015

Journal Articles

Up-Regulation of the PI3K Signaling Pathway Mediates Resistance to Idelalisib

Sarah Meadows, Sorensen Rick, Yahiaoui Anella, Jia Liu, PhD, Li Li, PhD, Peng Yue, PhD, Christophe Queva, PhD, Stacey Tannheimer, PhD

Blood (2015) 126 (23): 3707.

https://doi.org/10.1182/blood.V126.23.3707.3707

Published: 2015

Journal Articles

Combination of Idelalisib and ONO/GS-4059 in Lymphoma Cell Lines Sensitive and Resistant to BTK Inhibitors

Stacey Tannheimer, PhD, Jia Liu, PhD, Rick Sorensen, BS, Anella Yahiaoui, BS, Sarah Meadows, Li Li, PhD, Peng Yue, PhD, Kathleen S Keegan, PhD, Jamie Bates, PhD, Daniel Tumas, PhD DVM, Christophe Queva, PhD

Blood (2015) 126 (23): 3697.

https://doi.org/10.1182/blood.V126.23.3697.3697

Published: 2015

Journal Articles

The PI3K Delta Selective Inhibitor Idelalisib Minimally Interferes with Immune Effector Function and B Cell Depletion Mediated By Obinutuzumab (GA101) and Rituximab

Sylvia Herter, PhD, Adam Palazzo, Marina Bacac, PhD, Laura Grosmaire, MS, Christian Frey, PhD, Stefan Pflanz, PhD, Jia Liu, PhD, Stacey Tannheimer, PhD, Pablo Umana, PhD, Christian Klein, PhD, Christophe Queva, PhD

Blood (2014) 124 (21): 3342.

https://doi.org/10.1182/blood.V124.21.3342.3342

Published: 2014

NARROW

IGF1R as druggable target mediating PI3K-δ inhibitor resistance in a murine model of chronic lymphocytic leukemia

Acute Lymphoblastic Leukemia Cells Bypass the Blood Brain Barrier to Enter the CNS Via a Neuronal Developmental Pathway

The BET Inhibitor GS-626510 Converges with Idelalisib through the Inhibition of Tumor-Macrophage Crosstalk and Cytokine Production in Diffuse Large B-Cell Lymphoma

Enhanced Efficacy of the SYK Inhibitor Entospletinib and Chemotherapy in Infant Acute Lymphoblastic Leukemia

Idelalisib Interferes with the Crosstalk of Follicular Lymphoma and Its Immune Microenvironment and Potentiates the Activity of ABT-199

BI 836826, a Novel Fc-Engineered Antibody in Combination with Phosphoinositide-3-Kinase Inhibitor for Treatment of High Risk Chronic Lymphocytic Leukemia and Lymphoma

PI3Kδ Inhibition Suppresses Central Nervous System Involvement of Acute Lymphoblastic Leukemia

Evaluation of Idelalisib with B-Cell Receptor or Orthogonal Pathway Inhibitors in Diffuse Large B-Cell Lymphoma Cell Lines in Vitro and In Vivo

In Vivo modeling of Resistance to PI3Kδ Inhibitor Treatment Using EµTCL1-Tg Tumor Transfer Model

Combination of the BET Inhibitor GS-5829 and a BCL2 Inhibitor Resulted in Broader Activity in DLBCL and MCL Cell Lines

The Combination of a BET Inhibitor (GS-5829) and a BTK Inhibitor (GS-4059) Potentiates DLBCL Cell Line Cell Death and Reduces Expression of MYC, IL-10, and IL-6 in Vitro

PI3Kδ Inhibition Elicits Anti-Leukemic Effects through Bim-Dependent Apoptosis

Investigation of the Mechanism of Idelalisib Resistance in the Follicular Lymphoma WSU-Fsccl Cell Line

Up-Regulation of the PI3K Signaling Pathway Mediates Resistance to Idelalisib

Combination of Idelalisib and ONO/GS-4059 in Lymphoma Cell Lines Sensitive and Resistant to BTK Inhibitors

The PI3K Delta Selective Inhibitor Idelalisib Minimally Interferes with Immune Effector Function and B Cell Depletion Mediated By Obinutuzumab (GA101) and Rituximab

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only